ArticleArchives of microbiology2026
Purification and characterization of arginase from a new Aspergillus niger AUMC16187 isolate from sandy soil.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arginase is a therapeutic enzyme with promising anticancer applications, driving the search for novel microbial producers for this enzyme with superior properties. Here, we report a new fungal strain, identified morphologically and genetically as Aspergillus niger AUMC16187 (GenBank: OR447698), isolated from soil as a potent arginase producer. The enzyme was purified to homogeneity via Sephadex G-50 gel filtration and characterized as a dimeric, thermostable metalloenzyme, most active at 40 °C and stable over a broad temperature range. Crucially, the purified arginase exhibited significant and selective cytotoxicity against human epidermoid carcinoma (A431) cells, with lesser effects on normal human skin fibroblasts (HSF). Its therapeutic effect was confirmed by flow cytometry. The unique combination of biochemical robustness and selective anticancer activity in this novel A. niger arginase underscores its high potential as a promising biocatalyst for targeted cancer therapy and other biomedical applications.
Indexed as
Identifiers
42262449What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.